AMX0035 Significantly Slows Disease Progression in ALS, Phase 2 Study Shows
Updated results from the CENTAUR Phase 2 trial show that Amylyx‘s investigational oral treatment, AMX0035, significantly slowed progression in treated …
Articles by Inês Martins, PhD
Large ALS Data Analysis Reveals Common Genetic Cause of Disease
Researchers have found that mutations in the NEK1 gene are the most common genetic causes of amyotrophic lateral sclerosis (ALS), accounting…
ALS Patients May Safely Undergo Stem Cell Transplants, Study Reports
Transplanting human stem cells into the spinal cord of people with amyotrophic lateral sclerosis (ALS) may be safely accomplished, according…
Study Detects Early ALS in Mice Using Blood Levels of Copper Isotopes
Measuring copper concentration in the blood may allow for the diagnosis of amyotrophic lateral sclerosis (ALS) before the onset of clinical…
Neurodegenerative Diseases May Be Prevented by Autophagy Assisting Plant Compounds
Researchers at the University of Occupational and Environmental Health in Japan, reviewed advances for using natural plant compounds to regulate autophagy,…
Cerebrospinal Fluid of ALS Patients Has Reduced Levels of Anti-Inflammatory Protein, Revealing Potential New Therapeutic Target
Researchers from the Institute of Drug Research at the The Hebrew University in Israel have revealed that patients with amyotrophic lateral…